Research programme: CAR peptide therapeutics- VBS Pharmaceuticals

Drug Profile

Research programme: CAR peptide therapeutics- VBS Pharmaceuticals

Alternative Names: CAR-decorin; CAR-peptides; CARSKNKDC

Latest Information Update: 19 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VBS Pharmaceuticals
  • Class Antineoplastics; Peptides
  • Mechanism of Action Immunomodulators; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cachexia; Kidney disorders; Scars; Sepsis; Wounds

Most Recent Events

  • 31 Dec 2015 Preclinical trials in Breast cancer in USA (unspecified route)
  • 31 Dec 2015 Preclinical trials in Cachexia in USA (unspecified route)
  • 31 Dec 2015 Preclinical trials in Kidney disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top